Tuesday, August 16, 2022
Genprex (GNPX)
REQORSA Approved For Dose Escalation In Phase 1/2 Trial
Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Sufficient Safety Shown In First Cohort. Genprex announced that the first cohort from its Phase 1/2 Acclaim-1 trial in non-small cell lung cancer (NSCLC) has shown sufficient safety to allow treatment of a second cohort at a higher dose. This approval from the Safety Review Committee (SRC) after it analyzed patient data in the first cohort. Genprex expects all three cohorts in the Phase 1 portion to be completed by YE22.
Mechanism Of Action Could Improve Patient Survival. The Acclaim-1 study is Phase 1/2 trial testing the combination of REQORSA with Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC). This combines Tagrisso’s action as an EGF inhibitor with Requorsa’s delivery of the TUSC2 cancer suppressor gene. REQORSA adds the inhibition of several pathways leading to tumor growth and proliferation, and restores pathways that defend against cancer. The REQORSA combination has received Fast-Track designation for NSCLC from the FDA….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
